Waarom stijgt de aandelenkoers van EXELIXIS,?
Bulls zeggen
Patent protection
Federal Circuit ruling upheld patents covering the crystalline malate form of cabozantinib, preserving exclusivity and reducing the risk of early generic competition.
Competitive dynamics
Analyst view that Omcazio cannot be automatically substituted for Cabometyx and requires a dedicated commercial roll‑out, which limits immediate competitive pressure on cabozantinib sales.
Clinical expansion
A late‑stage trial combining zanzalintinib with an approved immunotherapy in kidney cancer has a high probability of success and could broaden zanzalintinib's commercial reach beyond colorectal cancer.
Regulatory scrutiny
FDA extended the review after requesting updated safety and efficacy data, signaling heightened regulatory scrutiny and increasing uncertainty around the approval path for zanzalintinib.
Dose tolerability
The selected clinical dose for zanzalintinib appears to increase serious side effects and led many patients to require dose reductions or delays, which could hinder real‑world treatment intensity and uptake.
Subgroup efficacy risk
Missing the overall survival co‑primary endpoint in patients without active liver metastases raises the risk that an approved label could exclude this subgroup and materially limit peak sales in colorectal cancer.
